High-dose N-acetylcysteine for long-term, regular treatment of early-stage chronic obstructive pulmonary disease (GOLD I–II): study protocol for a multicenter, double-blinded, para... by Heshen Tian, Yumin Zhou, Longhui Tang, Fan Wu, Zhishan Deng, Bijia Lin, Peiyu Huang, Shaodan Wei, Dongxing Zhao, Jingping Zheng, Nanshan Zhong, Pixin Ran

“…Measurements will include forced expiratory volume in 1 s (FEV1), the number of COPD exacerbations, health-related quality, and pharmacoeconomic analysis. Discussion Currently, there are no randomized controlled trials with high-dose N-acetylcysteine (600 mg twice daily) for patients with mild-to-moderate COPD (GOLD I–II). …”
Get full text

FEATURES OF PERIOPERATIVE MANAGEMENT OF PATIENTS AT LAPAROSCOPIC ANTIREFLUX INTERVENTIONS by V. I. Cherniy, I. V. Shtompel

“…Ourday the question is still remain, which of the methods of inhalation anesthesia Low flow anesthesia or Minimal flow anesthesia is better,  in the case of the requirements of comfort, patient’ safety and pharmacoeconomic feasibility.The principles of accelerated rehabilitation are possible not only if the surgical invasion is reduced, but also with the use of managed general anesthesia with adequate perioperative anesthesia.The operation of the patient in time is the best method of prevention of many early and delayed complications of the postoperative period. …”
Get full text

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis by Michal Sarfaty, Assaf Moore, Ashley M. Regazzi, Aaron P. Mitchell, Jonathan E. Rosenberg

“…Drug wastage was calculated by subtracting the actual administered dose from the total dose in an optimal set of vials. We built a pharmacoeconomic model to assess the financial impact of EV wastage annually in the US using the January 2021 Average Sales Prices from the Centers for Medicare and Medicaid Services. …”
Get full text

COMPARATIVE EFFICACY AND SAFETY OF HYPOLIPIDEMIC THERAPY WITH GENERIC AND ORIGINAL MEDICINAL PRODUCTS OF SIMVASTATIN by E. I. Tarlovskaya, Yu. A. Balandina, I. E. Sapozhnikova, N. S. Maksimchuk

“…To compare efficacy , safety and pharmacoeconomical characteristics of generic and original medicinal products of simvastatin in achievement of cholesterol and low density lipoprotein target levels. …”
Get full text

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review by Utian Wulf H

“…Additional costs include laboratory testing, management of adverse events, loss of productivity at work, and personal and miscellaneous costs. Pharmacoeconomic analyses, including those that consider risks identified by the Women's Health Initiative, generally support the cost-effectiveness of hormonal therapy for menopause-associated vasomotor symptoms, which have been the mainstay for the management of these symptoms for more than 50 years. …”
Get full text

Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives by Yayehrad AT, Siraj EA, Birhanu GB, Alemie AA, Derseh MT, Ambaye AS

“…The pharmaceutical, pharmacoeconomic, and regulatory aspects of these systems with currently achieved or predicted beneficial outcomes, challenges, and future perspectives are also highlighted.Keywords: nano-vaccine, nano-theranostics, nanoparticles, nanotechnology, SARS-CoV-2…”
Get full text

Customers' preferences and willingness to pay for a future dengue vaccination: a study of the empirical evidence in Vietnam by Vo TQ, Tran QV, Vo NX

“…However, introducing DV in Vietnam has met resistance from society and the government, influencing decisions about willingness-to-pay (WTP) and other pharmacoeconomic studies. This research aimed to evaluate the extent to which Vietnamese customers would be willing to pay to vaccinate themselves and their children, if any at all, against dengue.Materials and methods: This was a cross-sectional interview-based research. …”
Get full text

Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020 by Elias Mossialos, Wen Chen, Hongli Jiang, Wenhui Mao

“…China has initiated comprehensive drug policies to address different issues, including: (1) issuing or amending major regulations with changes in institutional settings; (2) implementing the marketing authorisation holder system and bioequivalence assessment to improve the quality of drugs; (3) leveraging accelerated market approval and insurance listing to encourage needs-driven innovation and improve the access to new drugs; (4) introducing compulsory licensing to address major public health threats when needed; (5) scaling up the National Essential Medicine Policy and introducing pharmacoeconomic evaluation in National Reimbursable Drug List to promote rational use of medicine and evidence-based selection; (6) applying differentiated pricing strategies and scaling up zero mark-up policies to form a new financing mechanism; (7) adapting bulk procurement and placing strict regulations on the supply chain management to ensure supply and reduce the cost; (8) empowering pharmacists to improve the rational use of medicine; and (9) using procurement and supply chain digital platforms to inform decision and improve efficiency. …”
Get full text

Omalizumab, an anti-immunoglobulin E antibody: state of the art by Incorvaia C, Mauro M, Russello M, Formigoni C, Riario-Sforza GG, Ridolo E

“…The drug also has a good safety profile and a pharmacoeconomic advantage due to a reduction in the number of hospitalizations for asthma attacks. …”
Get full text

Clinical aspects of antimicrobial therapy used in patients with urogenital infections by S S Vialov, T A Vasina

“…The patient's opinion was mainly used to evaluate outpatient pharmacoeconomic efficiency. Patient compliance with the given therapy was estimated by taking into account the specific features of prehospital care. …”
Get full text

Levetiracetam: review clinica ed economica di un nuovo antiepilettico by Orietta Zaniolo, Mario Eandi

“…A 1-year dose escalation decision model was set up in refractory patients who failed to respond to two or more other currently available therapies, with seizure freedom selected as the measure of effectiveness. Available pharmacoeconomic data show that the incremental cost of treating patients with levetiracetam is low when compared with the benefits of seizure freedom, at least in the UK. …”
Get full text

Clinical and economic studies of eptifibatide in coronary stenting by Pasala T, Sattayaprasert P, Bhat PK, Athappan G, Gandhi S

“…In patients receiving bivalirudin (a newer safer anticoagulant), routine use of eptifibatide is discouraged except in select situations (eg, angiographic complications). Although older pharmacoeconomic studies favor eptifibatide, in the current era of P2Y12 inhibitors and newer safer anticoagulants, the increased costs associated with bleeding make the routine use of eptifibatide an economically nonviable option. …”
Get full text

Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. by Elizabeth J J Berm, Margot de Looff, Bob Wilffert, Cornelis Boersma, Lieven Annemans, Stefan Vegter, Job F M van Boven, Maarten J Postma

“…We found that only the minority of recent pharmacoeconomic evaluations assessed the intrinsic value of the PGx tests. …”
Get full text

Costo/efficacia della prevenzione di infezioni alle prime vie aeree mediante un estratto batterico immunostimolante aspecifico (OM-85) by Orietta Zaniolo, Lorenzo Pradelli, Mario Eandi

“…OBJECTIVES: To estimate the pharmacoeconomical impact of preventing recurrent upper respiratory tract infections (URTIs) with OM-85, a non-specific immunostimulating agent, in at-risk children. …”
Get full text

Multiple criteria decision analysis approach to consider therapeutic innovations in the emergency department: The methoxyflurane organizational impact in acute trauma pain. by Virginie Eve Lvovschi, Maxime Maignan, Karim Tazarourte, Mohamed Lamine Diallo, Caroline Hadjadj-Baillot, Nathalie Pons-Kerjean, Frederic Lapostolle, Claude Dussart

“…CONCLUSIONS:Our model highlighted the putative positive organizational impact of methoxyflurane in the ED-particularly when supported by a trauma care pathway-and the relevance of expert consensus in this particular pharmacoeconomic context. The MCDA approach could be extended to other research fields and healthcare challenges in emergency medicine.…”
Get full text

Etonogestrel-releasing subdermal contraceptive implant: Budget impact analysis based on the Brazilian private healthcare system. by Agnaldo Lopes da Silva Filho, Ricardo Luis Pereira Bueno, Yohanna Ramires, Lara Marina Cruz Lino

“…Here, we demonstrate that the etonogestrel-releasing subdermal contraceptive implant (IMP-ETN) may be an appropriate and cost-effective alternative to levonorgestrel-releasing intrauterine systems (LNG-IUSs) for women in Brazil. For our pharmacoeconomic analysis, we reviewed the literature on IMP-ETN regarding its acceptance, eligibility criteria, choice, relations with age, adverse events and, finally, the unmet need in the fee-for-service private healthcare sector. …”
Get full text

Optimizing antibiotic therapy of group IV community-acquired pneumonia patients by Dziublyk Ya.O.

“…In current group of patients pharmacoeconomic analysis confirmed the expediency of administration a sequential antibiotic therapy with parenteral amoxicillin/clavulanat or ceftriaxone in combination with azithromycin, followed by oral amoxicillin/clavulanat or cefuroxime axetil in combination with azithromycin upon stabilization of patient’s condition.…”
Get full text

Dispositivos de medición de FENO by Marina Blanco-Aparicio, Francisco Javier González-Barcala, Alicia Padilla Galo

“…In addition, the existing comparative and pharmacoeconomic studies are analyzed so that professionals can make the choice of device guided by the most current evidence.…”
Get full text

Head to head comparison of the propensity score and the high-dimensional propensity score matching methods by Jason R. Guertin, Elham Rahme, Colin R. Dormuth, Jacques LeLorier

Get full text

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data by Harrington R, Al Nokhatha SA, Conway R

“…Additionally, we review the cost-benefit analyses of the available JAK inhibitors and address some of the pharmacoeconomic considerations for real-world practice in the UK and US by detailing the raw acquisition cost and the value they provide in comparison to the benchmark biologic adalimumab and the anchor DMARD methotrexate.Keywords: rheumatoid arthritis, immunosuppressive therapies, JAK inhibitors, targeted synthetic DMARD, tsDMARD…”
Get full text